Navigation Links
ImMAGE Biotherapeutics Closes Out 2016 in France as a YEi Laureate
Date:2/16/2017

PHILADELPHIA, Feb. 16, 2017 /PRNewswire-USNewswire/ -- ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage biotechnology company harnessing the power of the immune system to find a better treatment for triple negative breast cancer (TNBC), announced today their completion of the YEi Start in France program.

The YEi Start in France program is an accelerator designed to help entrepreneurs grow their business in France and Europe.  ImMAGE Biotherapeutics was one of eight American companies selected to complete an intensive one week immersion in France in December that provided introductions to an extensive customized business network and connections to the best resources in Europe.

"It was an honor to be included among the eight YEi laureates in 2016," said ImMAGE Biotherapeutics President and COO Mahesh Narayanan. "During the course of the program, I had the opportunity to meet with influential companies and investors, including potential partners and mentors that can support our potential expansion overseas."

Narayanan visited a number of research and cancer centers that could be potential clinical sites for ImMAGE in the future.  Among the centers were Gustave Roussy, a major cancer center in Europe that specializes in breast cancer, especially with early stage clinical trials; EFS, an immunotherapy research center; and CGFL, a research institute that specializes in using imaging to study biodistribution of drugs.

In addition, Narayanan met with companies that have potential to collaborate with ImMAGE, including Onxeo, an orphan oncology drug development company with four drugs currently in the pipeline, and Oncodesign, a preclinical contract research organization.

ImMAGE plans to start collaborating with many of these institutions over the next 12 months. Gustave Roussy and CHUV/CGFL are potential clinical sites for Europe. Oncodesign is a potential collaborator for the non-GLP efficacy studies, while Onxeo might be an early partner for future development of various candidates.

About ImMAGE Biotherapeutics
ImMAGE Biotherapeutics Corp. (OTCMKTS: IMMG) was founded in 2015 to harness the power of the human immune system to treat cancer. The company, which has a presence in the Washington, DC and Philadelphia regions, is developing multiple viable candidates to treat triple-negative breast cancer (TNBC) and has progressed from in-vitro trials to animal testing. The immunotherapy market is expected to grow to $9 billion by 2022 and may be used in up to 60% of cases of advanced cancer. Learn more at www.immagebio.com

CONTACT: Zhi Mou, 1-866-692-2939

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/immage-biotherapeutics-closes-out-2016-in-france-as-a-yei-laureate-300408909.html


'/>"/>
SOURCE ImMAGE Biotherapeutics
Copyright©2017 PR Newswire.
All rights reserved


Related biology technology :

1. ImMAGE Biotherapeutics to Present at the 9th Annual Biotech Showcase Conference
2. ImMAGE Biotherapeutics Announces Positive Results from Animal Studies
3. ImMAGE Biotherapeutics Announces Positive Results from In Vitro Trials
4. How These Biotech Stocks are Faring? -- Agenus, Tokai Pharma, Eleven Biotherapeutics, and Rexahn Pharma
5. Oxford BioTherapeutics Strengthens Board of Directors with Appointment of Two Biotech Veterans
6. Oxford Finance Provides $10 Million Senior Debt Facility to Oxford BioTherapeutics
7. Biotech Stocks on Investors Radar -- Eleven Biotherapeutics, Illumina, Sangamo Biosciences, and CytRx
8. Biotech Stocks on Investors Radar -- Northwest Biotherapeutics, ACADIA Pharma, Acorda Therapeutics, and Ultragenyx Pharma
9. Stealth BioTherapeutics To Present At 28th Annual Piper Jaffray Healthcare Conference
10. Stealth BioTherapeutics To Present At Stifel 2016 Healthcare Conference
11. Asterias Biotherapeutics Announces Treatment of First Spinal Cord Injury Patient with Maximum Dose of AST-OPC1 in SCiStar Clinical Trial
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2017)... ... April 26, 2017 , ... Looking for ... and cooking events company, offers one-of-a-kind gifts, ranging from gourmet cooking experiences to ... cuisine, and guests leave inspired with new cooking tips and techniques, thanks to ...
(Date:4/26/2017)... ... 2017 , ... NextSteps 2017, NetDimensions’ annual global user conference, ... May on the following dates: , ?    London, UK from May 10-11, ?    New Orleans, ... Performance Institute will be the opening keynote speaker at the NextSteps EMEA ...
(Date:4/25/2017)... ... April 25, 2017 , ... L3 Clinical Trials, the Clinical ... is now a certified iMedNet eClinical and Electronic Data Capture software designer for ... research team to build, customize and manage clinical trial data capture and databases ...
(Date:4/24/2017)... ... April 24, 2017 , ... ... denaturation in a cellular milieu; however, the broad application of this cellular target ... platforms with sensitive quantitative readouts. Cell-based thermal stabilization assays are valuable methods for ...
Breaking Biology Technology:
(Date:4/24/2017)... WASHINGTON , April 24, 2017 ... counsel and partner with  Identity Strategy Partners, LLP ... "With or without President Trump,s March 6, ... Foreign Terrorist Entry , refugee vetting can be instilled ... refugee resettlement. (Right now, all refugee applications are ...
(Date:4/19/2017)... York , April 19, 2017 ... as its vendor landscape is marked by the presence ... market is however held by five major players - ... Together these companies accounted for nearly 61% of the ... the leading companies in the global military biometrics market ...
(Date:4/18/2017)... a global expert in SoC-based imaging and computing solutions, has developed ... the company,s hybrid codec technology. A demonstration utilizing TeraFaces ® , ... showcased during the upcoming Medtec Japan at Tokyo Big Sight April ... Vegas Convention Center April 24-27. ... Click here for an image of the M820 ...
Breaking Biology News(10 mins):